Physicians' Academy for Cardiovascular Education

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA

Possible approaches in precision medicine for secundary CV prevention

10' education - Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

How to treat residual inflammatory risk?

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

3' education - May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##SCROLLER_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##SCROLLER_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##SCROLLER_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##SCROLLER_ITEMS_FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

10' education - Sep. 27, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management: diagnostics and guidelines

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

How to manage statin-intolerant patients?

3' education - June 11, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Erik Stroes
##SCROLLER_ITEMS_FULL_TITLE##

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov

CVRM Dubai

10' education - Sep. 15, 2014
##SCROLLER_ITEMS_FULL_TITLE##

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield

CV Risk Master Class Latin American chapter

10' education - Nov. 25, 2013

CV Risk Master Class

10' education - Oct. 14, 2013

Online CV Risk Master Class

10' education - Oct. 21, 2013

Online CV Risk Master Class - Español

10' education - Oct. 31, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CV Risk Master Class - Asian chapter

10' education - May 29, 2013

EAS Consensus Panel: CV benefits of statin therapy far outweigh any adverse effects

Literature - May 3, 2018 - Mach F et al., Eur Atheroscl Soc Consensus Panel - Eur Heart J, 2018

Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.

Updated ESC Guidelines on diagnosis and management of syncope

News - Apr. 30, 2018

A multidisciplinary ESC Task Force aimed to give as much practical advice as possible on the most appropriate management and therapy for each of the subtypes of syncope, although trial evidence is scarce.

Large interpersonal variation in estimated benefit from PCSK9 inhibition in CAD patients

Literature - Apr. 26, 2018 - Kaasenbrood L et al. - Heart 2018

The potential incremental benefit of PCSK9 inhibition varies a lot among patients with stable CAD, with the greatest benefit observed in younger patients with highest risk factor burden and high LCL-c levels.

Alcohol consumption affects different CVD events in different ways

Literature - Apr. 16, 2018 - Wood AM et al., - The Lancet 2018

In a large prospective study, risk of all-cause mortality increases above 100 g alcohol per week, and positive associations with alcohol intake were seen mostly for stroke and HF, as opposed to MI.

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy
Download your free copy

This document covers five topics that help cardiologists understand what is important when treating patients with diabetes, and which risks these patients face. Download your free copy.

New diabetes stratification predicts risk of complications

Literature - Mar. 7, 2018 - Ahlqvist E et al. - Lancet Diab Endocrinol 2018
In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.

In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.

There is no such thing as 'metabolically healthy obese', as it increases CHD risk

Literature - Feb. 7, 2018 - Lassale C et al., - Eur Heart J, 2018

A large pan-European study shows that overweight and obesity are associated with higher risk of CHD, even if the person does not have metabolic syndrome.

Adherence to healthy diets can overrule genetic predisposition for obesity

Literature - Jan. 29, 2018 - Wang T et al. - BMJ 2018

Improving adherence to healthy dietary patterns could attenuate the association between genetic predisposition and BMI and weight increases, particularly in individuals at high genetic risk.

Gestational DM not only increases risk of T2DM, but also of hypertension and IHD

Literature - Jan. 29, 2018 - Daly B et al., - PLoS Medicine, 2018

Population-based study shows that women with GDM are over 20 times more likely to develop T2DM and have an almost doubled risk of hypertension, and 2.8-fold higher risk of IHD, compared with control.

Guideline differences regarding statin treatment affect ASCVD event prevention

Literature - Jan. 17, 2018 - Mortensen MB and Nordestgaard BG. - Ann Intern Med 2018
Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Differential associations seen between Lp(a) levels and stroke, depending on AF-status

Literature - Jan. 9, 2018 - Aronis KN et al., - J Am Heart Assoc. 2017

In a prospective community-based cohort, Lp(a) ≥50 mg/dL was associated with higher stroke risk in those without AF, but not in those with AF, nor with an elevated risk of AF.